Latham & Watkins represented Evelo Biosciences in the transaction. Evelo Biosciences, Inc. (Nasdaq: EVLO) has announced the pricing of an underwritten public offering of 4,500,000 shares…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now